Overview

• Colossal acquired the University of Melbourne’s TIGGR thylacine lab and rebranded it as Colossal Australia, creating a permanent Melbourne hub.
• Professor Andrew Pask will lead global developmental biology as Chief Biology Officer, reporting to Colossal’s Chief Science Officer, Beth Shapiro.
• The expansion is backed by a major US investment described as substantially into eight figures to upgrade facilities and accelerate artificial gestation work.
• Researchers are integrating embryo culture, artificial wombs and pouch systems into continuous marsupial gestation, with a prototype Pask describes as visually simple but highly capable.
• Colossal is applying gene-editing tools to living species, including cane-toad toxin resistance in northern quolls under regulatory review and chytrid resistance in frogs, while thylacine gene editing is underway with a six-to-eight-year timeline for that phase.